Document:

Form of Non-Deferral RSU Agreement

 Exhibit 10.2 
 CADENCE PHARMACEUTICALS, INC. 
 2006 EQUITY INCENTIVE AWARD PLAN 
 RESTRICTED STOCK UNIT AWARD GRANT NOTICE AND 
 RESTRICTED STOCK UNIT AWARD AGREEMENT 
 Cadence Pharmaceuticals, Inc., a Delaware corporation (the
“Company”), pursuant to its 2006 Equity Incentive Award Plan (the “Plan”), hereby grants to the individual listed below (“Participant”), an award of restricted stock units
(“Restricted Stock Units” or “RSUs”) with respect to the number of shares of the Company’s common stock, par value $0.0001 (the “Shares”). This award for Restricted Stock
Units (this “RSU Award”) is subject to all of the terms and conditions as set forth herein and in the Restricted Stock Unit Award Agreement attached hereto as Exhibit A (the “Restricted Stock Unit
Agreement”) and the Plan, each of which are incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Grant Notice and the Restricted Stock Unit
Agreement. 
  

			
	Participant:	  	  

		
	Grant Date:	  	  

		
	Total Number of RSUs:	  	  

		
	Distribution Schedule:	  	Subject to the terms of the Restricted Stock Unit Agreement, the RSUs shall be distributable as they vest pursuant to the Vesting Schedule.
		
	Vesting Schedule:	  	 TO BE SPECIFIED IN INDIVIDUAL AGREEMENTS

 By his or her signature and the Company’s signature below, Participant agrees to be bound by
the terms and conditions of the Plan, the Restricted Stock Unit Agreement and this Grant Notice. Participant has reviewed the Restricted Stock Unit Agreement, the Plan and this Grant Notice in their entirety, has had an opportunity to obtain the
advice of counsel prior to executing this Grant Notice and fully understands all provisions of this Grant Notice, the Restricted Stock Unit Agreement and the Plan. Participant hereby agrees to accept as binding, conclusive and final all decisions or
interpretations of the Committee upon any questions arising under the Plan, this Grant Notice or the Restricted Stock Unit Agreement. 
  

									
	CADENCE PHARMACEUTICALS, INC.	 		 	PARTICIPANT
					
	By:	 	  
	 		 	By:	 	  

	Print Name:	 	  
	 		 	Print	 	  

	Title:	 	  
	 		 	Name:	 	  

	Address:	 	  
	 		 	Address:	 	  

		 	  
	 		 		 	  

 EXHIBIT A 
 TO RESTRICTED STOCK UNIT AWARD GRANT NOTICE 
 RESTRICTED STOCK UNIT AWARD AGREEMENT 

Pursuant to the Restricted Stock Unit Award Grant Notice (the “Grant Notice”) to which this Restricted Stock Unit Award
Agreement (this “Agreement”) is attached, the Company has granted to Participant the right to receive the number of RSUs set forth in the Grant Notice, subject to all of the terms and conditions set forth in this Agreement,
the Grant Notice and the Plan. 
 ARTICLE I. 
 GENERAL 
 1.1 Defined Terms. Wherever the following terms are used in this Agreement they
shall have the meanings specified below, unless the context clearly indicates otherwise. Capitalized terms not specifically defined herein shall have the meanings specified in the Plan and the Grant Notice. 
 (a) “Termination of Consultancy” shall mean the time when the engagement of the Participant as a Consultant to the Company or to
a Parent or Subsidiary is terminated for any reason, with or without cause, including, but not by way of limitation, by resignation, discharge, death or retirement, but excluding: (i) terminations where there is a simultaneous employment or
continuing employment of the Participant by the Company or any Parent or Subsidiary, and (ii) terminations where there is a simultaneous reestablishment of a consulting relationship or continuing consulting relationship between the Participant
and the Company or any Parent or Subsidiary. The Committee, in its absolute discretion, shall determine the effect of all matters and questions relating to Termination of Consultancy, including, but not by way of limitation, the question of whether
a particular leave of absence constitutes a Termination of Consultancy. Notwithstanding any other provision of the Plan, the Company or any Parent or Subsidiary has an absolute and unrestricted right to terminate a Consultant’s service at any
time for any reason whatsoever, with or without cause, except to the extent expressly provided otherwise in writing. 
 (b)
“Termination of Directorship” shall mean the time when the Participant, if he or she is or becomes an Independent Director, ceases to be a Director for any reason, including, but not by way of limitation, a termination by
resignation, failure to be elected, death or retirement. The Board, in its sole and absolute discretion, shall determine the effect of all matters and questions relating to Termination of Directorship with respect to Independent Directors.

 (c) “Termination of Employment” shall mean the time when the employee-employer relationship between the
Participant and the Company or any Parent or Subsidiary is terminated for any reason, with or without cause, including, but not by way of limitation, a termination by resignation, discharge, death, Disability or retirement; but excluding:
(i) terminations where there is a simultaneous reemployment or continuing employment of the Participant by the Company or any Parent or Subsidiary, and (ii) terminations where there is a simultaneous establishment of a consulting
relationship or continuing consulting relationship between the Participant and the Company or any Parent or Subsidiary. The Committee, in its absolute discretion, shall determine the effect of all matters and questions relating to Termination of
Employment, including, but not by way of limitation, the question of whether a particular leave of absence constitutes a Termination of Employment. 
  

 A-1 

 (d) “Termination of Services” shall mean the Participant’s Termination of
Consultancy, Termination of Directorship or Termination of Employment, as applicable. 
 1.2 Incorporation of Terms of Plan. The RSU
Award is subject to the terms and conditions of the Plan which are incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan shall control. 
 ARTICLE II. 
 AWARD OF RESTRICTED
STOCK UNITS 
 2.1 Award of Restricted Stock Units. 
 (a) Award. In consideration of Participant’s continued employment with or service to the Company or any Parent or Subsidiary thereof and for other good and valuable consideration, the Company hereby grants
to Participant the right to receive the number of RSUs set forth in the Grant Notice, subject to all of the terms and conditions set forth in this Agreement, the Grant Notice and the Plan. Prior to actual issuance of any Shares, the RSUs and the RSU
Award represent an unsecured obligation of the Company, payable only from the general assets of the Company. 
 (b) Vesting. The RSUs
subject to the RSU Award shall vest in accordance with the Vesting Schedule set forth in the Grant Notice. Unless and until the RSUs have vested in accordance with the vesting schedule set forth in the Grant Notice, Participant will have no right to
any distribution with respect to such RSUs. In the event of Participant’s Termination of Services prior to the vesting of all of the RSUs, any unvested RSUs will terminate automatically without any further action by the Company and be forfeited
without further notice and at no cost to the Company. Participant shall not be deemed to have a Termination of Services merely because of a change in the capacity in which Participant renders service to the Company or any Subsidiary or a change in
the entity for which Participant renders such service, unless following such change in capacity or service Participant is no longer serving as an Employee, Independent Director or consultant of the Company or any Subsidiary. 
 (c) Distribution of Shares. 
 (i)
Shares of Stock shall be distributed to Participant (or in the event of Participant’s death, to his or her estate) with respect to such Participant’s vested RSUs following the vesting date of the RSUs as specified in the Vesting Schedule
set forth in the Grant Notice, subject to the terms and provisions of the Plan and this Agreement. 
 (ii) All distributions shall be made
by the Company in the form of whole shares of Stock. 
 (iii) Neither the time nor form of distribution of Stock with respect to the RSUs
may be changed, except as may be permitted by the Committee in accordance with the Plan and Section 409A of the Code and the Treasury Regulations thereunder. 
 (d) Generally. Shares issued under the RSU Award shall be issued to Participant or Participant’s beneficiaries, as the case may be, at the sole discretion of the Committee, in either
(i) uncertificated form, with the Shares recorded in the name of Participant in the books and records of the Company’s transfer agent with appropriate notations regarding the restrictions on transfer imposed pursuant to this Agreement; or
(ii) certificate form. 
  

 A-2 

 2.2 Tax Withholding. Notwithstanding any other provision of this Agreement (including, without
limitation, Section 2.1(b) hereof): 
 (a) The Company has the authority to deduct or withhold, or require Participant to remit to the
Company, an amount sufficient to satisfy applicable federal, state, local and foreign taxes (including any FICA obligation) required by law to be withheld with respect to any taxable event arising from the receipt of the Shares upon settlement of
the RSUs. To the maximum extent permitted by law, the Company has the right to retain, without notice, from Shares issuable under the RSU Award or from other compensation payable to Participant, shares of Stock or cash having a value sufficient to
satisfy Participant’s tax withholding obligation. 
 (b) At any time not less than five business days before any such tax withholding
obligation arises, Participant may elect to satisfy his or her tax obligation, in whole or in part, by either: (i) electing to have the Company withhold from other cash compensation payable to Participant or Shares otherwise to be delivered to
Participant pursuant to the RSU Award with a Fair Market Value equal to the minimum amount of the tax withholding obligation, or (ii) paying the amount of the tax withholding obligation directly to the Company in cash. Unless Participant
chooses to satisfy his or her tax withholding obligation in accordance with clause (ii) above, Participant’s tax withholding obligation may be automatically satisfied in accordance with clause (i) above. The Committee will have the
right to disapprove an election to pay Participant’s tax withholding obligation under clause (ii) in its sole discretion. In the event Participant’s tax withholding obligation will be satisfied under clause (i) above, then the
Company, upon approval of the Committee, may elect (in lieu of withholding the applicable withholding taxes from other cash compensation payable to Participant or Shares to be delivered to Participant pursuant to the RSU Award) to instruct any
brokerage firm determined acceptable to the Company for such purpose to sell on Participant’s behalf a whole number of shares from those Shares issuable to Participant upon settlement of the RSUs as the Company determines to be appropriate to
generate cash proceeds sufficient to satisfy Participant’s tax withholding obligation. Participant’s acceptance of this RSU Award constitutes Participant’s instruction and authorization to the Company and such brokerage firm to
complete the transactions described in clause (i) above, including the transactions described in the previous sentence, as applicable. Any Shares to be sold at the Company’s direction through a broker-assisted sale will be sold on the day
the tax withholding obligation arises (i.e., the date Stock is delivered) or as soon thereafter as practicable. The Shares may be sold as part of a block trade with other participants of the Plan in which all participants receive an average price.
Participant will be responsible for all broker’s fees and other costs of sale, and Participant agrees to indemnify and hold the Company harmless from any losses, costs, damages, or expenses relating to any such sale. To the extent the proceeds
of such sale exceed Participant’s tax withholding obligation, the Company agrees to pay such excess in cash to Participant as soon as practicable. Participant acknowledges that the Company or its designee is under no obligation to arrange for
such sale at any particular price, and that the proceeds of any such sale may not be sufficient to satisfy Participant’s tax withholding obligation. The Company may refuse to issue any Shares in settlement of the RSU Award to Participant until
the foregoing tax withholding obligations are satisfied. 
 (b) Conditions to Issuance of Shares. The Company shall not be required to
issue or deliver any Shares issuable upon the vesting of the RSUs prior to the fulfillment of all of the following conditions: (i) the admission of the Shares to listing on all stock exchanges on which such Shares are then listed, (ii) the
completion of any registration or other qualification of the Shares under any state or federal law or under rulings or regulations of the U.S. Securities and Exchange Commission or other governmental regulatory body, which the Committee shall, in
its sole and absolute discretion, deem necessary and advisable, (iii) the obtaining of any approval or other clearance from any state or federal governmental agency that the Committee shall, in its absolute discretion, determine to be necessary
or advisable, (iv) the lapse of any such reasonable period of time following the date the RSUs vest as the Committee may from time to time establish for reasons of administrative convenience and (v) the receipt by the Company of full
payment of any applicable withholding tax in any manner permitted under Section 2.2(a) above. 
  

 A-3 

 ARTICLE III. 
 OTHER PROVISIONS 
 3.1 RSU Award and Interests Not Transferable. This RSU Award and the rights
and privileges conferred hereby, including the RSUs awarded hereunder, shall not be liable for the debts, contracts or engagements of Participant or his or her successors in interest or shall be subject to disposition by transfer, alienation,
anticipation, pledge, encumbrance, assignment or any other means whether such disposition be voluntary or involuntary or by operation of law by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including
bankruptcy), and any attempted disposition thereof shall be null and void and of no effect. 
 3.2 Rights as Stockholder. Neither
Participant nor any person claiming under or through Participant shall have any of the rights or privileges of a stockholder of the Company in respect of any Shares issuable hereunder unless and until certificates representing such Shares (which may
be in uncertificated form) will have been issued and recorded on the books and records of the Company or its transfer agents or registrars, and delivered to Participant (including through electronic delivery to a brokerage account). After such
issuance, recordation and delivery, Participant shall have all the rights of a stockholder of the Company, including with respect to the right to vote the Shares and the right to receive any cash or share dividends or other distributions paid to or
made with respect to the Shares. 
 3.3 Adjustments. The Participant acknowledges that the RSU Award is subject to modification and
termination in certain events as provided in this Agreement and Article 11 of the Plan. 
 3.4 Not a Contract of Employment or other
Service Relationship. Nothing in this Agreement or in the Plan shall confer upon Participant any right to continue to serve as an employee or other service provider of the Company or any of its affiliates. 
 3.5 Construction. This Agreement shall be administered, interpreted and enforced under the laws of the State of Delaware without regard to
conflicts of laws thereof. Should any provision of this Agreement be determined by a court of law to be illegal or unenforceable, the other provisions shall nevertheless remain effective and shall remain enforceable. 
 3.6 Conformity to Securities Laws. Participant acknowledges that the Plan and this Agreement are intended to conform to the extent necessary with
all provisions of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all regulations and rules promulgated thereunder by the U.S. Securities and
Exchange Commission, including, without limitation, Rule 16b-3 under the Exchange Act. Notwithstanding anything herein to the contrary, the Plan shall be administered, and the Awards are granted, only in such a manner as to conform to such laws,
rules and regulations. To the extent permitted by applicable law, the Plan and this Agreement shall be deemed amended to the extent necessary to conform to such laws, rules and regulations. 
 3.7 Amendment, Suspension and Termination. To the extent permitted by the Plan, this Agreement may be wholly or partially amended or otherwise
modified, suspended or terminated at any time or from time to time by the Committee or the Board, provided, that, except as may otherwise be provided by the Plan, no amendment, modification, suspension or termination of this Agreement shall
adversely effect the Option in any material way without the prior written consent of the Participant. 
  

 A-4 

 3.8 Notices. Any notice to be given under the terms of this Agreement to the Company shall be
addressed to the Company in care of the Secretary of the Company at the address given beneath the signature of an authorized officer of the Company on the Grant Notice, and any notice to be given to Participant shall be addressed to Participant at
the address given beneath Participant’s signature on the Grant Notice. By a notice given pursuant to this Section 3.8, either party may hereafter designate a different address for notices to be given to that party. Any notice shall be
deemed duly given when sent via email or when sent by certified mail (return receipt requested) and deposited (with postage prepaid) in a post office or branch post office regularly maintained by the United States Postal Service. 
 3.9 Successors and Assigns. The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement
shall inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer herein set forth, this Agreement shall be binding upon Participant and his or her heirs, executors, administrators, successors and
assigns. 
 3.10 Section 409A. 
 (a) Notwithstanding any other provision of the Plan, this Agreement or the Grant Notice, the Plan, this Agreement and the Grant Notice shall be interpreted in accordance with, and incorporate the terms and conditions
required by, Section 409A of the Code (together with any Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the date
hereof, “Section 409A”). The Committee may, in its discretion, adopt such amendments to the Plan, this Agreement or the Grant Notice or adopt other policies and procedures (including amendments, policies and procedures with
retroactive effect), or take any other actions, as the Committee determines are necessary or appropriate to comply with the requirements of Section 409A. 
 (b) This Agreement is not intended to provide for any deferral of compensation subject to Section 409A of the Code, and,
accordingly, the Shares issuable pursuant to the RSUs hereunder shall be distributed to Participant no later than the later of: (i) the fifteenth (15th) day of the third month following Participant’s first taxable year in which such RSUs are no longer subject to a
substantial risk of forfeiture, and (ii) the fifteenth (15th) day of the
third month following first taxable year of the Company in which such RSUs are no longer subject to substantial risk of forfeiture, as determined in accordance with Section 409A and any Treasury Regulations and other guidance issued thereunder.

 3.11 Tax Representations. Participant has reviewed with Participant’s own tax advisors the federal, state, local and foreign
tax consequences of this investment and the transactions contemplated by the Grant Notice and this Agreement. Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents.
Participant understands that Participant (and not the Company) shall be responsible for Participant’s own tax liability that may arise as a result of this investment or the transactions contemplated by this Agreement. 
 3.12 Entire Agreement. The Plan, the Grant Notice and this Agreement (including all exhibits thereto) constitute the entire agreement of the
parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof. 
 3.13 Titles. Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement. 
 3.14 Governing Law; Severability. The laws of the State of Delaware shall govern the interpretation, validity, administration, enforcement and
performance of the terms of this Agreement regardless of the law that might be applied under principles of conflicts of laws. 
  

 A-5License Agreement

 Exhibit 10.1 
 LICENSE AGREEMENT 
 This Agreement made effective as of this 27
th day of August, 2009 (the “Effective Date”), by and between Northwestern
University, an Illinois corporation having a principal office at 633 Clark Street, Evanston, Illinois 60208 (hereinafter referred to as “Northwestern”) and Catalyst Pharmaceutical Partners, Inc., a Delaware corporation having a principal
office at 355 Alhambra Circle, Suite 1370, Coral Gables, FL, 33134 (hereinafter referred to as “Licensee”) (each a “Party” and collectively the “Parties”). 
 WITNESSETH 
 WHEREAS, Northwestern is the owner of certain patents
and patent application listed on Exhibit A and has the right to grant licenses under such patents and patent application, subject only to a royalty-free, nonexclusive license heretofore granted to the United States Government;

 WHEREAS, Northwestern desires to have such patent rights, and know-how developed and commercialized to benefit the public and is
willing to grant a license hereunder; 
 WHEREAS, Licensee has represented to Northwestern that Licensee has the expertise,
experience, and resources necessary to enable Licensee to commit itself to a diligent program to develop and subsequently manufacture, market and sell products utilizing such patent rights and know-how; 
 WHEREAS, Licensee desires to obtain a license under such patent rights and know-how upon the terms and conditions hereafter set forth; 

NOW THEREFORE, in consideration of the premises and mutual covenants contained herein, the Parties hereto agree as follows: 
 ARTICLE I - DEFINITIONS 
 1.1
“Affiliate” shall mean any corporation, firm, partnership or other entity which controls, is controlled by or is under common control with a Party. For the purposes of this definition, “control” shall mean any right or
collection of rights that together allow direction on any vote with respect to any action by an entity or the direction of management and operations of that entity. Such right or collection of rights includes without limitation (a) the
authority to act as sole member or shareholder or partner with a majority interest in an entity; (b) a majority interest in an entity; and (c) the authority to appoint, elect, or approve at least a majority of the governing board of that
entity. 
 1.2 “FDA” shall mean the United States Food & Drug Administration and any successor agency thereto.

 1.3 “Field” shall mean treatment of neurological conditions (including addiction) in humans by means of altering
biochemical pathways associated with such conditions. 
  

 1 

 1.4 “IND” shall mean an Investigational New Drug Application as described in 21 C.F.R.
§ 312.20 et seq. (as the same may be amended from time to time). 
 1.5 “Know-How” shall mean technical information
existing as of the Effective Date which is owned by Northwestern and directly relates to practicing inventions described in Patent Rights. 
 1.6 “Licensed Products” shall mean all products and services of Licensee, its Affiliates and its sublicensees covered by or which incorporate or are developed or made using the Patent Rights or Know-How. 
 1.7 “NDA” shall mean an application submitted to the FDA for approval to market a new drug, as described in 21 C.F.R. § 314.50 et
seq. (as the same may be amended from time to time). 
 1.8 “Net Sales” shall mean the gross amount invoiced by Licensee or
its Affiliates to unaffiliated third parties for the sale of Licensed Products, less (a) trade credits, discounts, rebates and allowances actually granted on account of price adjustments, rebate programs, billing errors or the rejection or
return of goods, (b) all costs of shipping, freight, transportation and insurance for the Licensed Product, but only to the extent that such costs are included in Licensee’s or its Affiliate’s invoice price to its customers for the
Licensed Product, and (c) all sales, use, excise and other taxes and compulsory payments to governmental authorities (including tariffs and customs duties) that are included in Licensee’s or its Affiliate’s invoice price to its
customers for the Product. 
 In the event that the Licensed Product is sold in a fixed combination (“Combination Product”) with one or more active
therapeutic compounds not subject to this Agreement (“Other Items”), the invoice price of such Combination Product shall be set by Licensee in good faith, applying a standard of fair and honest dealing with Northwestern, and Net Sales in
each country of the Licensed Product included in the Combination Product shall be determined using the following formulae: 
  

	 	(a)	If the Licensed Product and Other Items contained in the combination are sold separately in such country, the Net Sales for purposes of calculating royalty payments will be the
result obtained by multiplying the Net Sales of the Combination Product in such country by the fraction A/A+B, where A is the invoiced price in such country of the Licensed Product in the Combination Product, and B is the invoiced price in such
country of all Other Items in the Combination Product. 

  

	 	(b)	If the Combination Product includes Other Items which are not sold separately in such country (but the Licensed Product contained in the Combination Product is sold separately in
such country), the Net Sales for purposes of calculating royalty payments will be the result of multiplying the Net Sales of the Combination Product in such country by the fraction A/C, where A is as defined above and C is the invoiced price in such
country of the Combination Product. 

  

	 	(c)	 If neither the Licensed Product nor the Other Items contained in the Combination Product are sold separately, or if only the Licensed Product is not sold
separately, Licensee shall in good faith, applying a standard of fair and honest dealing with 

  

 2 

	 	 
Northwestern, propose, after discussion with Northwestern, the percentage of the revenue from such Combination Product in such country that is attributable
to the Licensed Product and shall notify Northwestern in writing of such proposal not less than 45 days prior to commencing sales of such Combination Product. Unless Licensee receives written objection from Northwestern to such proposal within 45
days following Northwestern’s receipt of such proposal, then the revenue so attributed to the Licensed Product shall be the Net Sales for the purposes of this paragraph. In the event Northwestern objects to Licensee’s proposal,
Northwestern and Licensee agree to negotiate in good faith to reach a mutually acceptable determination, and Licensee shall not market such Combination Product unless and until such a determination is reached. 

 1.9 “Patent Rights” shall mean the patents and patent application listed on Exhibit A attached hereto and incorporated
herein by reference, and any patents which issue from such patent application, and all divisions, continuations and continuations-in-part, reissues, reexaminations or extensions of any thereof, to the extent that such are supported by the
specification and entitled to the priority date of the patents or pending patent application in Exhibit A. Patent Rights shall also include any foreign counterparts of any of the foregoing. 
 1.10 “Regulatory Approval” shall mean the approval of either the FDA or of a foreign counterpart thereto required to commence commercial
sale of a Licensed Product in such country in the Territory in which such foreign counterpart has jurisdiction. 
 1.11
“Territory” shall mean the World. 
 1.12 “Launch” shall mean, in each country of the Territory, the first
commercial sale of a Licensed Product by or on behalf of Licensee or its Affiliates or its sublicensees in such country following the Regulatory Approval of such Licensed Product in such country. 
 ARTICLE II - GRANT 
 2.1 In
reliance upon the representations made to Northwestern by Licensee that Licensee has the experience, expertise and resources necessary to enable Licensee to perform its obligations hereunder, Northwestern hereby grants to Licensee and its Affiliates
an exclusive license under Patent Rights and Know-How to make, have made, use, import, offer for sale and sell Licensed Products in the Territory in the Field. 
 2.2 The grant under Paragraph 2.1 shall be subject to the obligations of Northwestern and of Licensee to the United States Government under any and all applicable laws, regulations, and executive orders including
those set forth in 35 U.S.C. §200, et seq. 
 2.3 Northwestern and all inventors of Patent Rights retain the right to utilize Patent
Rights and Know-How for noncommercial research and educational purposes. Northwestern also retains the rights to distribute certain materials upon request by the research community for academic purposes through a Material Transfer Agreement (MTA),
in compliance with NIH guidelines. 
 2.4 The grant of this license does not obligate Northwestern or any inventor of Patent Rights to make
available to Licensee, its sublicensees or Affiliates for their own use and benefit, Northwestern space, facilities, students and services, unless otherwise stated herein or in a separate contractual agreement between Northwestern and Licensee.

  

 3 

 2.5 Northwestern hereby grants to Licensee the right to grant sublicenses consistent with this Agreement
provided that Licensee shall be responsible for the performance of its sublicensees, including the payment of royalties, and shall provide Northwestern with executed copies of such sublicense agreements within thirty (30) days of
execution of such agreements. Northwestern shall treat all such sublicense agreements and the terms thereof as confidential information of Licensee in accordance with Section 3.1. 
 2.6 The grant of this license shall not include research or discoveries that arise from collaborations between inventors of Patent Rights and other
faculty investigators at Northwestern or outside Northwestern. 
 ARTICLE III - CONFIDENTIAL INFORMATION 
 3.1 (a) Northwestern and Licensee each agree that all information contained in documents marked “Confidential” which are forwarded to one by
the other shall be received in strict confidence, used only for the purposes of this Agreement, and not disclosed by the recipient (subject to paragraph (e) of this Section 3.1), its agents or employees to any third party without the prior
written consent of an authorized officer of the disclosing Party, unless such information (i) was in the public domain at the time of disclosure, (ii) later became part of the public domain through no act or omission of the recipient, its
employees, agents, successors or assigns, (iii) was lawfully disclosed to the recipient by a third party having the right to disclose it, (iv) was already known by the recipient at the time of disclosure (as evidenced by recipient’s
written records), (v) was independently developed by recipient (as evidenced by recipient’s written records) or (vi) is required to be submitted to a government agency to obtain and maintain the approvals and clearances of Licensed
Products. 
 (b) Disclosure may be made to Affiliates, distributors, customers, and agents, to nonclinical and clinical investigators, and to
consultants, where necessary or desirable with appropriate safeguards to protect the confidential underlying disclosure. Either recipient may disclose confidential information of the disclosing Party (to the extent such disclosure is reasonably
necessary) to such Party’s outside counsel, accountants, or agents and to bankers and other third parties in connection with due diligence or similar investigations; provided in each case that any such consultant, banker, lawyer,
accountant, agent or third party is bound by obligations of confidentiality and non-use at least as restrictive as those set forth herein. 
 (c) Northwestern and Licensee also agree that confidential information may be orally disclosed by one Party to the other Party. Such information shall be confirmed in writing and designated “Confidential” within thirty
(30) days of disclosure for the provisions of this Article III to apply. 
 (d) The fact that a particular item of know-how or
information does not at the time of disclosure or generation qualify as (or subsequently ceases to qualify as) confidential information by virtue of one or more of the exclusions specified in paragraph (a) (the “Excluded Item”) will
not relieve the recipient from its obligation of confidentiality and non-use as to any other item of confidential information of the disclosing party or as to the relationship of the Excluded Item to any other item of confidential information of the
disclosing party. 
  

 4 

 (e) If, based upon the advice of legal counsel skilled in the subject matter, the recipient is required
to disclose confidential information of the disclosing party to comply with an applicable law, regulation, legal process, or order of a government authority or court of competent jurisdiction, the recipient may disclose such confidential information
only to the person or entity required to receive such disclosure; provided, however, that the recipient required to disclose such confidential information shall (i) to the extent reasonably practicable, give prior notice to such
disclosing Party to enable it to seek any available exemptions from or limitations on such disclosure requirement and shall reasonably cooperate in such efforts by the disclosing Party, (ii) furnish only the portion of the confidential
information which is legally required to be disclosed, based upon the advice of legal counsel skilled in the subject matter, (iii) use all reasonable efforts to secure confidential protection of such confidential information, and
(iv) continue otherwise to perform its obligations of confidentiality set out herein as to such confidential information.
 3.2 Each
Party’s obligation of confidence hereunder shall be fulfilled by using at least the same degree of care with the other Party’s confidential information as it uses to protect its own confidential information but in any event not less than
reasonable care. This obligation shall exist while this Agreement is in force and for a period of two (2) years thereafter except in the event of termination by Northwestern for breach on the part of Licensee, in which event Licensee’s
obligation to maintain Northwestern’s information confidential will exist for a period of ten (10) years after the termination for breach. The provisions of this Article III shall survive termination of this Agreement. 
 3.3 This Agreement may be distributed solely (a) to those employees, agents and independent contractors of Northwestern and Licensee who have a need
to know its contents, (b) to those persons whose knowledge of its contents will facilitate performance of the obligations of the parties under this Agreement, (c) to those persons, if any, whose knowledge of its contents is essential in
order to permit Licensee or Northwestern to maintain or secure the benefits under policies of insurance, (d) subject to paragraph (e) of Section 3.1, as may be required by law or regulation or by court or administrative agency order,
or (e) such other persons as may be permitted by paragraph (b) of Section 3.1. Notwithstanding, Licensor acknowledges Licensee’s representations (i) that Licensee is a company with a class of securities registered under
Section 12 of the Securities Exchange Act of 1934 and (ii) that as a result Licensee will be obligated to disclose this Agreement in its reports to the U.S. Securities and Exchange Commission (“Commission”) and to file a copy of
same as an exhibit to its reports to the Commission. 
 ARTICLE IV - MILESTONES AND DUE DILIGENCE 
 4.1 Licensee hereby represents that Licensee has the experience, expertise and resources necessary to enable Licensee to perform its obligations
hereunder. Licensee shall use commercially reasonable efforts to develop and commercialize Licensed Products (assuming US clinical trial protocols). Licensee shall, upon execution of this Agreement, submit to Northwestern a preliminary development
and business plan that sets forth an outline of Licensee’s intended efforts to develop and commercialize Licensed Products. Such plan shall include a reasonably detailed description of the tasks generally anticipated to be performed for the
development of Licensed Products in relation to the milestones set forth in Section 4.2 and estimates of anticipated expenses. 
  

 5 

 4.2 The parties agree that if all milestones listed on Exhibit B are met, Licensee will be
deemed to be using commercially reasonable efforts to develop and commercialize Licensed Products. 
 4.3 The parties agree that if any
milestone payment listed on Exhibit C, Section 2, is not met, Licensee will be deemed to be in breach. 
 4.4 The parties acknowledge
that the process of drug development involves many variables and uncertainties. Therefore, the failure to adhere to specific aspects of the preliminary development and business plan shall not, without more, give rise to any right to terminate this
Agreement; provided, however, that Northwestern shall not be precluded from considering the preliminary development and business plan as part of its evaluation of whether Licensee’s development efforts are commercially reasonable
so long as it also considers any additional information provided by Licensee regarding factors affecting such development efforts. 
 4.5
Licensee agrees to provide annual progress reports with sufficient details to Northwestern describing Licensee’s research and development efforts in the development of Licensed Products during the preceding year. Such progress reports shall be
due each January, beginning January 2010, until the date of first commercial sale of a Licensed Product. 
 ARTICLE V - PAYMENTS

 In consideration of the license granted by Northwestern to Licensee under this Agreement, Licensee shall pay to Northwestern the
amounts listed in Exhibit C hereto. 
 ARTICLE VI - PAYMENT, REPORTS AND RECORDS 
 6.1 Payment Dates and Reports 
 Within
sixty (60) days after the end of each calendar quarter of each year during the term of this Agreement (and within sixty (60) days after the end of the first calendar quarter which ends following the expiration of this Agreement), Licensee
shall pay to Northwestern all amounts which have become due and payable during such calendar quarter. Such payments shall be accompanied by a statement showing the Net Sales of each Licensed Product by Licensee and its Affiliates in each country,
the applicable royalty rate and the calculation of the amount of royalty due, as well as all amounts of Sublicensing Revenue received and a calculation of Northwestern’s share thereof. 
 6.2 Accounting 
 a. Payments in
U.S. Dollars 
 All dollar sums referred to in this Agreement are expressed in U.S. dollars and the Net Sales used for calculating the
royalties and other sums payable to Northwestern by Licensee pursuant to Paragraph 6.1 shall be computed in U.S. dollars. All payments of such sums and royalties shall be made in U.S. dollars. For purposes of determining the amount of royalties due,
the amount of Net Sales in any foreign currency shall be computed by converting such amount into U.S. dollars at the prevailing commercial rate of exchange for purchasing U.S. dollars with such foreign currency in question as quoted by Citibank in
New York on the last business day of the calendar quarter for which the relevant royalty payment is to be made by Licensee. 
  

 6 

 b. Blocked Royalties 
 Notwithstanding the foregoing, if by reason of any restrictive exchange laws or regulations Licensee or any Affiliate or sublicensee hereunder shall be
unable to convert to U.S. dollars an amount equivalent to the royalty payable by Licensee hereunder in respect of Licensed Product sold for funds other than U.S. dollars, Licensee shall notify Northwestern promptly with an explanation of the
circumstances. In such event, payment of any royalties due hereunder which are so restricted shall be deferred and paid in U.S. dollars as soon as reasonably possible after, and to the extent that, such restrictive exchange laws or regulations are
lifted so as to permit such conversion to United States dollars, of which lifting Licensee shall promptly notify Northwestern. At its option, Northwestern shall meanwhile have the right to request the payment (to it or to a nominee), and upon such
request Licensee shall pay, or cause to be paid, all such amounts (or such portions thereof as are specified by Northwestern) in funds, other than U.S. dollars, designated by Northwestern and legally available to Licensee under such then existing
restrictive exchange laws or regulations. 
 6.3 Records 
 (a) Licensee shall keep, and shall cause its Affiliates and sublicensees to keep, for three (3) years following the date on which a quarterly report is delivered and all payments due as reflected in such report
have been paid, complete and accurate records for such quarter of sales of each Licensed Product by Licensee or its Affiliates and Sublicensing Revenue received from its sublicensees. Such records shall be kept in sufficient detail to enable the
amounts payable to be determined accurately. Northwestern shall have the right during this period of three (3) years after receiving any such report to appoint, at its expense, an independent certified public accountant to inspect the relevant
records of Licensee and its Affiliates to verify such report. Northwestern shall submit the name of said accountant to Licensee for approval; said approval shall not be unreasonably withheld, delayed or conditioned. Licensee shall make its relevant
records and those of its Affiliates available for inspection by such independent certified public accountant. Such inspection shall be conducted during regular business hours at such place or places where such records are customarily kept, upon
reasonable notice from Northwestern, to the extent necessary to verify the accuracy of the reports and payments with not more than one (1) inspection per calendar year. Northwestern shall have no right to inspect any quarter more than once,
absent a demonstration of a reasonable basis therefor. 
 (b) Northwestern agrees to hold in strict confidence all information concerning
royalty payments and reports, and all information learned in the course of any audit or inspection, except to the extent necessary for Northwestern to reveal such information in order to enforce its rights under this Agreement or as may be required
by law (in accordance with Section 3.1(e)). 
 (c) If royalties are understated by five percent (5%) or more in Licensee’s
favor, the Licensee shall, within ten (10) days of receipt of the audit report, pay the balance due Northwestern plus all reasonable costs of the audit or inspection and interest at the prime rate as quoted in effect from time to time by
Citibank in New York (the “Adjustment Rate”) from the date at which such unpaid amount would have otherwise been due and payable. If royalties are understated by less than five percent (5%), Licensee shall include such unpaid amount with
the next scheduled payment pursuant to Paragraph 6.1. If royalties are overstated in Northwestern’s favor, 

  

 7 

 
then Licensee shall be entitled to a credit against the next scheduled payment to be made following the inspection pursuant to Paragraph 6.1 in an amount
equal to the amount of the overpayment, 
 ARTICLE VII - PUBLICATION 
 Subject to this paragraph, Northwestern will have the right, at its discretion, to publish the results of any of its research related to the Patent
Rights or Know-How and use any information for purposes of research, teaching, and other educationally-related matters. In order to avoid loss of Patent Rights as a result of premature disclosure of patentable information, Northwestern shall submit
any prepublication or predisclosure material that are related to the Patent Rights and where Richard Silverman is a co-author to the Licensee for review at least thirty (30) days prior to planned submission for publication or disclosure.
Licensee shall notify Northwestern within twenty (20) days after it receives such material as to: (1) whether it desires Northwestern to file patent applications on any inventions contained in the material, in which case Northwestern shall
proceed to file a patent application at the expense of Licensee and add such patent application to Exhibit A, so long as it fulfills Patent Rights; (2) whether Licensee requests a delay in publication, in which case Northwestern agrees to delay
publication for a maximum of an additional twenty-one (21) days; and (3) whether such materials contain confidential information of Licensee, in which case Northwestern shall, at Licensee’s request, delete said confidential
information from the intended publication. 
 ARTICLE VIII - PATENT PROSECUTION 
 8.1 Northwestern shall apply for, seek prompt issuance of, and maintain during the term of this Agreement the Patent Rights in the United States and in
the foreign countries, if any, listed in Exhibit A hereto. Exhibit A may be amended by verbal agreement of both parties, such agreement to be confirmed in writing within ten (10) days. The prosecution, filing and maintenance of all Patent
Rights shall be the responsibility and obligation of Northwestern; provided, however, Licensee shall have reasonable opportunities to advise Northwestern and shall cooperate with Northwestern in such prosecution, filing and
maintenance. 
 8.2 For the avoidance of doubt, payment of all fees and costs relating to the filing, prosecution, and maintenance of Patent
Rights shall be the responsibility of Licensee, whether such fees and costs were incurred before or after the Effective Date. 
 ARTICLE
IX - INFRINGEMENT 
 9.1 Each party shall inform the other promptly in writing of any alleged infringement of the Patent Rights by a
third party of which it becomes aware and of any available evidence thereof. 
 9.2 Licensee, at its expense, will have first right to
enforce Patent Rights against infringement by third parties. Licensee may, for such purposes, use the name of Northwestern as party plaintiff; provided, however, that such right to bring such infringement action shall remain in effect
only for so long as the license granted herein remains exclusive. No settlement, consent judgment or other voluntary final disposition of the suit may be entered into without the consent of Northwestern, which consent shall not be unreasonably
withheld, delayed or conditioned. Licensee shall indemnify Northwestern against any order for costs that may be made against Northwestern in such proceedings. 
  

 8 

 9.3 If Licensee recovers any damages or other sums in such action, suit or proceeding, or in settlement
thereof, such damages or other sums recovered shall first be applied to all out-of-pocket costs and expenses incurred by Licensee and by Northwestern in connection therewith, including, with limitation, attorneys fees. If after such reimbursement
any funds shall remain from such damages or other sums recovered, such funds shall be retained by Licensee; provided, however, that Northwestern shall receive out of any such remaining recovery received by Licensee an amount as follows: (i) as
to ordinary damages, Northwestern shall receive payment equivalent to payments that would have been due to Northwestern as royalties under Exhibit C, Section 4 had the infringing sales that Catalyst lost to the infringer been made by Catalyst,
and (ii) as to special or punitive damages, Northwestern shall receive payment equivalent to payments that would have been due to Northwestern as Sublicensing Revenue Share as specified under Exhibit C, Section 5. 
 9.4 If Licensee does not file suit against an infringer of Patent Rights within 6 months of knowledge thereof, during the term of this Agreement,
Northwestern shall have the right, but shall not be obligated, to prosecute at its own expense all infringements of the Patent Rights and, in furtherance of such right, Licensee hereby agrees that Northwestern may include Licensee as a party
plaintiff in such suit, without expense to Licensee. The total cost of any such infringement action commenced or defended solely by Northwestern shall be borne by Northwestern and Northwestern shall keep any recovery or damages for past infringement
derived therefrom. 
 9.5 In the event that a declaratory judgment action alleging invalidity or noninfringement of any of the Patent Rights
shall be brought against Licensee, Northwestern, at its option, shall have the right, within thirty (30) days after it receives notice of the commencement of such action, to intervene and take over the sole defense of the action at its own
expense. 
 9.6 In any infringement suit that either Party may institute to enforce the Patent Rights pursuant to this Agreement, the other
party hereto shall, at the request and expense of the Party initiating such suit, cooperate with all reasonable requests of the other Party, including, to the extent reasonably possible, having its employees testify when requested and making
available relevant records, papers, information, samples, specimens, and the like. 
 9.7 Licensee, during the term of this Agreement, shall
have the sole right in accordance with the terms and conditions herein to sublicense any alleged infringer for future use of the Patent Rights. Any consideration received as part of such a sublicense shall be treated as Sublicensing Revenue pursuant
to Exhibit C, Section 5. 
 ARTICLE X - PRODUCT LIABILITY 
 10.1 Licensee shall at all times during the term of this Agreement and thereafter, indemnify, defend and hold Northwestern, its trustees, directors,
officers, employees and Affiliates, harmless against all claims, proceedings, demands and liabilities of any kind whatsoever, including reasonable attorneys’ fees and expenses, (a) arising out of the death of or injury to any person or
persons or out of any damage to property resulting from the production, manufacture, sale, use, lease, consumption or advertisement of the Licensed Product(s) or (b) arising from any obligation of Licensee hereunder. 
  

 9 

 10.2 Prior to the manufacture of the Licensed Product for the purpose of introducing it into humans and
the actual introduction of the Licensed Product into humans, Licensee shall obtain and carry in full force and effect commercial, general liability insurance which shall protect Licensee and Northwestern with respect to events covered by paragraph
10.1 (a) above. Such insurance shall be written by a reputable insurance company authorized to do business in the State of Illinois, shall list Northwestern as an additional named insured thereunder, shall be endorsed to include product
liability coverage and shall require thirty (30) days written notice to be given to Northwestern prior to any cancellation or material change thereof. The limits of such insurance shall not be less than Five Million Dollars ($5,000,000) per
occurrence with an aggregate of Fifteen Million Dollars ($15,000,000) for personal injury or death, and One Million Dollars ($1,000,000) per occurrence with an aggregate of Three Million Dollars ($3,000,000) for property damage. Licensee shall
provide Northwestern with Certificates of Insurance evidencing the same. 
 10.3 EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT,
NORTHWESTERN, ITS TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES, AND AFFILIATES MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE, VALIDITY OF PATENT RIGHTS CLAIMS, ISSUED OR PENDING AND THE ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE. NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION MADE OR WARRANTY GIVEN BY NORTHWESTERN THAT THE
PRACTICE BY LICENSEE OF THE LICENSE GRANTED HEREUNDER SHALL NOT INFRINGE THE PATENT RIGHTS OF ANY THIRD PARTY. IN NO EVENT SHALL NORTHWESTERN, ITS TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES AND AFFILIATES BE LIABLE FOR INCIDENTAL OR CONSEQUENTIAL
DAMAGES OF ANY KIND, INCLUDING ECONOMIC DAMAGE OR INJURY TO PROPERTY AND LOST PROFITS, REGARDLESS OF WHETHER NORTHWESTERN SHALL BE ADVISED, SHALL HAVE OTHER REASON TO KNOW, OR IN FACT SHALL KNOW OF THE POSSIBILITY. 
 ARTICLE XI - TERM AND TERMINATION 
 11.1 This Agreement shall become effective on the Effective Date. Unless sooner terminated as provided for below, this Agreement shall continue in effect, on a country-by-country basis, (a) until the expiration of the last to expire of
any Patent Rights or (b) ten (10) years from the date of the first commercial sale in countries where no Patent Rights exist. 
 11.2 Licensee shall have the right to terminate this Agreement in whole or in part anytime after three (3) years from the Effective Date by giving Northwestern sixty (60) days written notice. 
 11.3 Subject to Licensee’s right to notice and a cure period as specified in Section 11.7, Northwestern shall have the right to terminate or
render this license non-exclusive at any time after three (3) years from the Effective Date if, in Northwestern’s reasonable judgment, Licensee has breached any of its obligations hereunder. 
  

 10 

 11.4 This Agreement shall be terminated immediately and shall be of no further force and effect if
Licensee fails to make the payment of the license fee required by Section 1(b) of Exhibit C. 
 11.5 The provisions of Article III
(Confidentiality), Article V (Payments), Article VI (Payments, Reports and Records), Article X (Product Liability) and Article XIII (Dispute Resolution) shall survive termination or expiration of this Agreement in accordance with their terms.

 11.6 If (1) Licensee makes any general assignment for the benefit of its creditors; (2) a petition is filed by or against
Licensee, or any proceeding is initiated against Licensee as a debtor, under any bankruptcy or insolvency law, unless the laws then in effect void the effectiveness of this provision; or (3) a receiver, trustee, or any similar officer is
appointed to take possession, custody, or control of all or any part of Licensee’s assets or property, then Northwestern may immediately terminate the license granted by this Agreement upon written notice to Licensee of such termination.

 11.7 If either Party breaches any material obligation imposed by this Agreement, then the other Party may at its option, send a written
notice to the Party in breach that it intends to terminate the license granted by this Agreement. If the Party in breach does not cure the breach within ninety (90) days from the notice date, then the other Party shall have the right to
terminate the license granted immediately upon the date of mailing of a written notice of termination to the Party in breach. 
 11.8 Upon
termination of this Agreement for any cause, nothing herein shall be construed to release either Party of any obligation that has matured prior to the effective date of such termination. Licensee may, after the date of such termination, sell all
Licensed Products that it may have on hand at the date of termination, provided that it pays the earned royalty thereon as provided in this Agreement. 
 11.9 In the event of termination for breach by Licensee, Licensee agrees to no longer use any of the Patent Rights or Know-How under which it has been granted a license, and will turn over and assign to Northwestern
its Regulatory Approvals and data and material related to price and Regulatory Approvals at no charge with the right to sublicense. 
 11.10
Upon termination of this Agreement, any and all existing sublicense agreements shall be immediately assigned to Northwestern, and Northwestern agrees to keep them in force to the extent that Northwestern is capable of performing as a licensor in
place of Licensee. 
 ARTICLE XII - ASSIGNMENT 
 12.1 Due to the nature and purpose of this Agreement, the Parties agree that a material element of this Agreement is that Northwestern has selected Catalyst Pharmaceutical Partners, Inc to serve as the licensee under
this Agreement based on the representations made by Catalyst Pharmaceutical Partners, Inc that it has the experience, expertise and resources necessary to enable it to perform the obligations of the license hereunder. Accordingly, the Parties agree
that this Agreement, the license granted hereunder, and the obligations of Licensee hereunder shall not be assigned, sublicensed (unless herein granted), or otherwise transferred by the Licensee without the prior written consent of Northwestern.
Notwithstanding any assignment or transfer permitted 

  

 11 

 
under this Paragraph 12.1, Licensee shall remain fully liable to Northwestern for the performance of the assignee or transferee, unless Northwestern’s
consent expressly releases Licensee from such liability.
 12.2 It is the understanding of the Parties that in the event a bankruptcy
petition is filed by or against Licensee, or any proceeding is initiated against Licensee as a debtor under any bankruptcy or insolvency law, applicable law excuses Northwestern from accepting performance from or rendering performance to an entity
other than Licensee, and Licensee, or trustee operating on behalf of the Licensee, shall be prohibited from assigning, sublicensing, or otherwise transferring the license granted hereunder and/or the obligations of Licensee hereunder without the
prior written consent of Northwestern. 
 12.3 Notwithstanding Sections 12.1 and 12.2, the parties agree that Licensee may assign the
Agreement to an acquirer of all or substantially all of Licensee’s assets and business related to the Patent Rights; provided, however, that no such assignment will be effective unless and until the assignee delivers to
Northwestern such assignee’s agreement in writing to assume and perform all of Licensee’s obligations under the Agreement, in which case Licensee shall be relieved of any further liability under this Agreement. 
 ARTICLE XIII - DISPUTE RESOLUTION 
 13.1 The Parties agree to effect all reasonable efforts to resolve any and all disputes between them in connection with this Agreement in an amicable manner. 
 13.2 The Parties agree that any dispute that arises in connection with this Agreement and which cannot be amicably resolved by the parties shall be resolved by binding Alternative Dispute Resolution (ADR) in the
manner set forth in Paragraph 13.3 through Paragraph 13.5. 
 13.3 If a Party intends to begin ADR to resolve a dispute, such Party shall
provide written notice to the other Party informing the other Party of such intention and the issues to be resolved. Within ten (10) business days after its receipt of such notice, the other Party may, by written notice to the Party initiating
ADR, add additional issues to be resolved. If the Parties cannot agree upon the selection of a neutral within twenty (20) business days following receipt of the original ADR notice, a neutral shall be selected by the then President of the
Center for Public Resources (CPR), 680 Fifth Avenue, New York, New York 10019. The neutral shall be a single individual having experience in the pharmaceutical industry relating to drug development and commercialization who shall preside in
resolution of any disputes between the Parties. The neutral selected shall not be an employee, director or shareholder of either Party or an Affiliate or sublicensee. 
 13.4 Each Party shall have ten (10) business days from the date the neutral is selected to object in good faith to the selection of that person. If either Party makes such an objection, the then President of the
CPR shall, as soon as possible thereafter, select another neutral under the same conditions as set forth above. This second selection shall be final. 
 13.5 The ADR shall be conducted in the following manner: 
 (a) No later than forty-five (45) business
days after selection, the neutral shall hold a hearing to resolve each of the issues identified by the Parties. 
  

 12 

 (b) At least five (5) days prior to the hearing, each Party must submit to the neutral and serve on
the other Party a proposed ruling on each issue to be resolved. Such proposed ruling shall contain no argument on or analysis of the facts or issues, and shall be limited to not more than fifty (50) pages. 
 (c) The neutral shall not require or permit any discovery by any means, including depositions, interrogatories or production of documents. 
 (d) Each Party shall be entitled to no more than eight (8) hours of hearing to present testimony or documentary evidence. The testimony of both
Parties shall be presented during consecutive calendar days. Such time limitation shall apply to any direct, cross or rebuttal testimony, but such time limitation shall only be charged against the Party conducting such direct, cross or rebuttal
testimony. It shall be the responsibility of the neutral to determine whether the parties have had the eight (8) hours to which each is entitled. 
 (e) Each Party shall have the right to be represented by counsel. The neutral shall have the sole discretion with regard to the admissibility of any evidence. 
 (f) The neutral shall rule on each disputed issue within thirty (30) days following the completion of the testimony of both Parties. Such ruling
shall adopt in its entirety the proposed ruling of one of the parties on each disputed issue. 
 (g) ADR shall take place in Chicago,
Illinois. All costs incurred for a hearing room shall be shared equally between the Parties. 
 (h) The neutral shall be paid a reasonable
fee plus expenses, which fees and expenses shall be shared equally by the Parties. 
 (i) The ruling shall be binding on the Parties and may
be entered as an enforceable judgment by a state or federal court having jurisdiction of the Parties. 
 13.6 This Article XIII shall survive
any termination of this Agreement. 
 ARTICLE XIV - NOTICES AND PAYMENTS 
 Any payment, notice or other communication pursuant to this Agreement shall be sufficiently made or given on the date of mailing if sent to such Party by
certified first class mail, postage prepaid, addressed to it at its address below or as it shall designate by written notice given to the other Party: 
  

			
	In the case of Northwestern:	  	Executive Director
		  	Technology Transfer Program
		  	Northwestern University
		  	1800 Sherman Avenue, Suite 504
		  	Evanston, Illinois 60201
		
	In the case of Licensee:	  	President
		  	Catalyst Pharmaceutical Partners, Inc
		  	355 Alhambra Circle
		  	Suite 1370
		  	Coral Gables, FL 33134

  

 13 

 ARTICLE XV - GENERAL 
 15.1 Force Majeure. Neither party shall be liable to the other for its failure to perform any of its obligations under this Agreement, except for
payment obligations, during any period in which such performance is delayed because rendered impracticable or impossible due to circumstances beyond its reasonable control, including without limitation earthquakes, governmental regulation, fire,
flood, labor difficulties, interruption of supply of key raw materials, civil disorder, and acts of God, provided that the Party experiencing the delay promptly notifies the other Party of the delay. 
 15.2 Severability. In the event any provision of this Agreement is held to be invalid or unenforceable, the valid or enforceable portion thereof
and the remaining provisions of this Agreement will remain in full force and effect. 
 15.3 Applicable Law. This Agreement is made in
accordance with and shall be governed and construed under the laws of the State of Illinois, excluding its choice of law rules. 
 15.4
Entire Agreement. This Agreement and the exhibits attached hereto constitute the entire, final agreement between the Parties with respect to the subject matter of this Agreement, and supersede all previous agreements or representations,
written or oral, with respect thereto. This Agreement may not be modified or amended except in a writing signed by a duly authorized representative of each Party. 
 15.5 Headings. The headings for each article and section in this Agreement have been inserted for convenience or reference only and are not intended to limit or expand on the meaning of the language contained
in the particular article or section. 
 15.6 Independent Contractors. The Parties are not employees or legal representatives of the
other party for any purpose. Neither Party shall have the authority to enter into any contracts in the name of or on behalf of the other Party. 
 15.7 Advertising. Licensee shall not use the name of the inventor listed in Exhibit A of this Agreement, of any institution with which the inventor has been or is connected, nor the name of Northwestern, in any advertising,
promotional or sales literature, without prior written consent obtained from Northwestern in each case. 
 15.8 Waiver. Any waiver
(express or implied) by either Party of any breach of this Agreement shall not constitute a waiver of any other or subsequent breach. 
 15.9
Counterparts. This Agreement may be executed in counterparts with the same force and effect as if each of the signatories had executed the same instrument. 
 15.10 Patent Marking. Licensee agrees to mark the Licensed Products sold in the United States with all applicable United States patent numbers. All Licensed Products shipped to or sold in other countries shall
be marked in such a manner as to conform with the patent laws and practice of the country of manufacture or sale. 
 [Signatures on
Following Page] 
  

 14 

 IN WITNESS WHEREOF, the Parties have executed this Agreement effective as of the Effective Date.

  

									
	CATALYST PHARMACEUTICAL PARTNERS, INC.	 		 	NORTHWESTERN UNIVERSITY
					
	By:	 	 /s/ Patrick J. McEnany
	 		 	By:	 	 /s/ Indrani Mukharji

	Name:	 	Patrick J. McEnany	 		 	Name:	 	Indrani Mukharji, Ph.D.
	Title:	 	President	 		 	Title:	 	Executive Director, Technology Transfer Program

  

 15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00162-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00162-of-00352.parquet"}]]